These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 12528473)

  • 21. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study.
    Bjøro K; Bell H; Hellum KB; Skaug K; Raknerud N; Sandvei P; Døskeland B; Maeland A; Lund-Tønnesen S; Myrvang B
    Scand J Gastroenterol; 2002 Feb; 37(2):226-32. PubMed ID: 11843062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
    Scott LJ; Perry CM
    Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re-treating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: really safe and effective?
    Lo GH
    Hepatology; 2009 Sep; 50(3):988; author reply 988-9. PubMed ID: 19714721
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: a multicenter controlled study.
    Xie Y; Xu DZ; Lu ZM; Luo KX; Jia JD; Wang YM; Zhao GZ; Zhang SL; Zhang DZ
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):369-74. PubMed ID: 15313671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated interferon: new preparation. Chronic hepatitis C: advantageous for some patients, but more data needed.
    Prescrire Int; 2003 Dec; 12(68):206-10. PubMed ID: 14986684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C.
    Moskovitz DN; Manoharan P; Heathcote EJ
    Can J Gastroenterol; 2003 Aug; 17(8):479-82. PubMed ID: 12945008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated hepatic transaminases associated with the use of interferon alfacon-1 and ribavirin.
    Kleppinger EL; Ragan AP
    Am J Health Syst Pharm; 2009 Mar; 66(5):465-8. PubMed ID: 19233994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters.
    Gowen BB; Smee DF; Wong MH; Pace AM; Jung KH; Bailey KW; Blatt LM; Sidwell RW
    Antivir Chem Chemother; 2006; 17(4):175-83. PubMed ID: 17066896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune thrombocytopenic purpura in a patient treated with interferon alfacon-1.
    Dimitroulopoulos D; Dourakis SP; Xinopoulos D; Tsamakidis K; Paraskevas E
    J Viral Hepat; 2004 Sep; 11(5):477-8. PubMed ID: 15357656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-infection by serologically-silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver.
    Fukuda R; Ishimura N; Hamamoto S; Moritani M; Uchida Y; Ishihara S; Akagi S; Watanabe M; Kinoshita Y
    J Med Virol; 2001 Mar; 63(3):220-7. PubMed ID: 11170061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cutaneous mucinosis and skin necrosis complicates interferon alfacon-1 (consensus interferon) treatment of chronic hepatitis C.
    Siewert E; Weyers W; Dietrich CG; Geier A; Lammert F; Matern S
    Eur J Med Res; 2005 Feb; 10(2):63-7. PubMed ID: 15817424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discordance between serum alanine aminotransferase (ALT) and virologic response to IFN-alpha2b in chronic hepatitis C patients with high and low pretreatment serum hepatitis C virus RNA titers.
    Blatt LM; Tong MJ; McHutchison JG; Russell J; Schmid P; Conrad A
    J Interferon Cytokine Res; 1998 Feb; 18(2):75-80. PubMed ID: 9506457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon alfacon-1: new preparation. Basically a me-too interferon alfa.
    Prescrire Int; 2003 Jun; 12(65):95-6. PubMed ID: 12825573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
    Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
    Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C.
    Lee JW; Kim W; Kwon EK; Kim Y; Shin HM; Kim DH; Min CK; Choi JY; Lee WW; Choi MS; Kim BG; Cho NH
    PLoS One; 2017; 12(6):e0179094. PubMed ID: 28614389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
    Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
    Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
    Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
    Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
    Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
    AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
    Alaimo G; Di Marco V; Ferraro D; Di Stefano R; Porrovecchio S; D'Angelo F; Calvaruso V; Craxì A; Almasio PL
    World J Gastroenterol; 2006 Nov; 12(42):6861-4. PubMed ID: 17106937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Interferon alpha, gamma, omega before and during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin].
    Bolewska B; Czajka A; Moczko J; Juszczyk J
    Przegl Epidemiol; 2007; 61(4):755-63. PubMed ID: 18572508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.